about
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionVitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirinEmerging therapies for hepatitis CThe Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary reportIdentification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report.New treatments for chronic hepatitis C: an overview for paediatricians.Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents.Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis CSuppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor
P2860
Q26775825-EBB86E13-B22B-4701-9083-2596411AA2F4Q26784321-48247E61-B75A-4E3E-8647-D821946C0FAEQ26853642-F00F9649-CA9D-4217-9520-4BAF2611A538Q33621649-60EE20EE-39B4-4FA0-A432-56CCBA23EFFBQ35674832-57FBF686-27A6-4371-8231-10EB14870828Q36744202-35AC3C8C-CED3-4FD5-ACF3-4E00891C8874Q37715878-2655F689-8EF5-4D52-84FD-CDFFF309642EQ38282842-28DB8DCD-9823-4277-8860-950D6E159A6EQ38295831-F70789DE-E0F9-4177-9F02-B3D016A9D1C6Q39034453-D912C715-88F8-4351-B088-13896D745C82Q40054110-A3C5D5D6-6C8D-481D-B706-2BE675943994Q52579185-AB713B6E-9B24-455E-9771-3C3B3B5BE192Q53684076-23AFC9B2-D069-4534-8C9D-1B5D7636DEBAQ56395991-EB2A2C7F-1A1B-4BFD-95BE-4282C710E4BAQ58697050-925FC8EC-0441-4956-B0EA-BE3BC04CAD68
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Daclatasvir: potential role in hepatitis C
@ast
Daclatasvir: potential role in hepatitis C
@en
Daclatasvir: potential role in hepatitis C
@nl
type
label
Daclatasvir: potential role in hepatitis C
@ast
Daclatasvir: potential role in hepatitis C
@en
Daclatasvir: potential role in hepatitis C
@nl
prefLabel
Daclatasvir: potential role in hepatitis C
@ast
Daclatasvir: potential role in hepatitis C
@en
Daclatasvir: potential role in hepatitis C
@nl
P2860
P356
P1476
Daclatasvir: potential role in hepatitis C
@en
P2093
Choongho Lee
P2860
P304
P356
10.2147/DDDT.S40310
P407
P577
2013-01-01T00:00:00Z
2013-10-16T00:00:00Z